Clinical Trial Update: ChangE From Any Systemic psoriasiS therapY to Raptiva [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating switching chronic plaque psoriasis patients from any systemic therapy to Raptiva (efalizumab); the study was terminated with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Raptiva (efalizumab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Chronic Plaque Psoriasis | Phase 4 | Status: TERMINATED | Results posted: 2010-08-30